Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 12, Issue 1, Pages 113-118Publisher
INFORMA HEALTHCARE
DOI: 10.1517/14712598.2012.642359
Keywords
asthma; benralizumab; IL-5; IL-5R alpha; MEDI-563
Funding
- National Center for Research Resources, National Institutes of Health [UL1RR029876]
Ask authors/readers for more resources
Introduction: Benralizumab is a monoclonal antibody that binds the a subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available